Oncocyte Corp Appoints New Directors, Updates Executive Contracts
Ticker: IMDX · Form: 8-K · Filed: Mar 10, 2025 · CIK: 1642380
Sentiment: neutral
Topics: board-changes, executive-compensation, management-changes
TL;DR
Oncocyte adds 2 directors, signs new deals with CEO/CFO.
AI Summary
On March 4, 2025, Oncocyte Corporation announced changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. David E.I. চুম্বন and Mr. David L. Levison, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. Joshua H. Schulman, and its Chief Financial Officer, Mr. Michael R. Gannon, effective March 4, 2025.
Why It Matters
The appointment of new directors and updated executive contracts can signal strategic shifts or confidence in leadership, potentially impacting the company's future direction and investor sentiment.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal restructuring or strategic pivots, which carry inherent risks.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- Dr. David E.I. চুম্বন (person) — Newly elected Director
- Mr. David L. Levison (person) — Newly elected Director
- Dr. Joshua H. Schulman (person) — Chief Executive Officer
- Mr. Michael R. Gannon (person) — Chief Financial Officer
- March 4, 2025 (date) — Effective date of changes
FAQ
Who were the new directors appointed to Oncocyte Corporation's Board?
Oncocyte Corporation appointed Dr. David E.I. চুম্বন and Mr. David L. Levison as new directors to its Board.
When were the new employment agreements for the CEO and CFO effective?
The new employment agreements for the Chief Executive Officer, Dr. Joshua H. Schulman, and Chief Financial Officer, Mr. Michael R. Gannon, were effective March 4, 2025.
What is Oncocyte Corporation's state of incorporation?
Oncocyte Corporation is incorporated in California.
What is the principal executive office address for Oncocyte Corporation?
The principal executive office address for Oncocyte Corporation is 15 Cushing, Irvine, California 92618.
What is the SIC code for Oncocyte Corporation?
The Standard Industrial Classification (SIC) code for Oncocyte Corporation is 2835, which corresponds to IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 10, 2025 by Dr. David E.I. চুম্বন regarding Oncocyte Corp (IMDX).